Department of Radiation Oncology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Int J Clin Oncol. 2021 Jul;26(7):1203-1211. doi: 10.1007/s10147-021-01921-z. Epub 2021 Apr 12.
Lymphoepithelioma-like carcinoma (LELC) is a rare histological types of solid tumors. The present study aims to comprehensively describe the demographic and clinical features of LELC using surveillance, epidemiology, and end results (SEER) database, with an emphasis on the prognostic difference according to primary tumor sites of LELC.
A population cohort with histologically diagnosed LELC were identified from SEER database between 1973 and 2016. Age-adjusted incidence rates and cancer-specific survival (CSS) were determined. Cox-regression proportional hazards model was used for both univariate and multivariate analyses.
In total, 2106 patients with LELC were identified, with the most common diagnosed primary tumor site of nasopharyngeal LELC (56.22%), followed by non-nasopharyngeal head and neck LELC (21.32%) and respiratory system (7.83%). The overall age-adjusted incidence of LELC was 0.091 per 100,000. The CSS rates of LELC patients at 5, 10, 15, and 20 years were 76%, 69%, 65%, and 61%, respectively. A tendency of decreasing incidence of LELC was observed in the past decade. Univariate analysis indicated that sex [hazard ratio (HR) 1.21, p = 0.031], year of diagnosis (HR 0.60 and 0.63, p < 0.001), race (HR 1.29, p = 0.0021), age (HR 1.25, p = 0.0072), summary tumor stage (HR 1.97, and 4.57, both p < 0.001), number of positive LN(HR2.21, p < 0.001), surgery (HR 0.58, p = 0.0033), chemotherapy (HR 1.19, p = 0.037) and primary tumor site (p < 0.001) were significant factors associated with prognosis of LELC. In multivariate analysis, age (HR 1.75, p = 0.03), distant stage (HR 6.57, p = 0.0001), number of positive LN (HR 2.63, p = 0.0015) and non-nasopharyngeal head and neck LELC (HR 0.37, p = 0.0031) were significantly independent predictors for CSS of LELC. In sub-group analysis, radiotherapy significantly improves CSS for nasopharyngeal LELC (HR 0.57, p = 0.0002), while surgery significantly improve CSS for non-nasopharyngeal LELC (HR 0.33, p < 0.0001).
Based on SEER data analysis, age older than 50 years, distant stage and more than three positive LN are significantly associated with worse CSS for LELC, while the prognosis of non-nasopharyngeal head and neck LELC is significantly better than nasopharyngeal LELC. Local treatments for LELC could be recommended according to primary tumor sites.
淋巴上皮样癌(LELC)是一种罕见的实体瘤组织学类型。本研究旨在利用监测、流行病学和最终结果(SEER)数据库全面描述 LELC 的人口统计学和临床特征,并重点关注 LELC 原发肿瘤部位的预后差异。
从 1973 年至 2016 年的 SEER 数据库中确定了经组织学诊断为 LELC 的人群队列。确定了年龄调整后的发病率和癌症特异性生存率(CSS)。Cox 回归比例风险模型用于单因素和多因素分析。
共确定了 2106 例 LELC 患者,最常见的诊断原发肿瘤部位为鼻咽 LELC(56.22%),其次为非鼻咽头颈部 LELC(21.32%)和呼吸系统(7.83%)。LELC 的总体年龄调整发病率为 0.091/10 万。LELC 患者的 CSS 率在 5、10、15 和 20 年时分别为 76%、69%、65%和 61%。过去十年,LELC 的发病率呈下降趋势。单因素分析表明,性别[风险比(HR)1.21,p=0.031]、诊断年份(HR 0.60 和 0.63,p<0.001)、种族(HR 1.29,p=0.0021)、年龄(HR 1.25,p=0.0072)、总肿瘤分期(HR 1.97 和 4.57,均 p<0.001)、阳性淋巴结数量(HR 2.21,p<0.001)、手术(HR 0.58,p=0.0033)、化疗(HR 1.19,p=0.037)和原发肿瘤部位(p<0.001)是与 LELC 预后相关的显著因素。多因素分析表明,年龄(HR 1.75,p=0.03)、远处分期(HR 6.57,p=0.0001)、阳性淋巴结数量(HR 2.63,p=0.0015)和非鼻咽头颈部 LELC(HR 0.37,p=0.0031)是 LELC CSS 的显著独立预测因素。亚组分析表明,放疗显著提高了鼻咽 LELC 的 CSS(HR 0.57,p=0.0002),而手术显著提高了非鼻咽头颈部 LELC 的 CSS(HR 0.33,p<0.0001)。
基于 SEER 数据分析,年龄大于 50 岁、远处分期和三个以上阳性淋巴结与 LELC 的 CSS 显著相关,而非鼻咽头颈部 LELC 的预后明显优于鼻咽 LELC。可以根据原发肿瘤部位推荐 LELC 的局部治疗。